affecting >10 million Indians per year. Worsening HF leads to pulmonary congestion and Edema , can result in unplanned readmission & early death. ~67.4% of USA and ~30.1% of Indian HF patients get readmitted to hospital within 1 year of initial hospitalization, with mortality rate of ~35.8% and ~23% respectively.

We are going to address the mortality rates arising from HF patients that are at home, post-discharge from hospital after undergoing various medical interventions such as angioplasty, bypass, cardiac catheterization etc. The most important metric of HF mortality is the number of readmissions after first hospitalization. Therefore, if we are able to detect early signs of HF deterioration, we may prevent serious crisis e.g. likelihood of unplanned hospitalization.

HF is associated with worsening hemodynamics, and increase in vascular resistance & pulmonary congestion. Therefore, change in pulmonary artery pressure, and vascular resistance, are observed in days and weeks prior to decompensation. Our product is the first and only patient vital and hemodynamic monitoring patent-pending wearable, that investigates if adverse HF events can be identified prior to occurrence through non-invasive monitoring. We are changing lives by delivering a lower cost clinically evidenced solution, to the global chronically ill population.